Updated acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from the South American Working Group (ConsenSur II);Neumonía aguda adquirida en la comunidad en adultos: Actualización de los lineamientos para el tratamiento antimicrobiano inicial basado en la evidencia local del grupo de trabajo de sudamérica (consensur ii)

Revista Chilena de Infectologia

Volumn 27, Issue SUPPL. 1, 2010, Pages 9-38

  Bantar, Carlos ^a   Curcio, Daniel ^b   Jasovich, Abel ^c   Bagnulo, Homero ^d   Arango, Álvaro ^e   Bavestrello, Luis ^f   Famiglietti, Angela ^g   García, Patricia ^h   Lopardo, Gustavo ⁱ   Losanovscky, Miriam ^j   Martínez, Ernesto ^k   Pedreira, Walter ^d   Piñeyro, Luis ^d   Remolif, Christian ^l   Rossi, Flavia ^m   Varón, Y Fabio ⁿ  

^a HOSPITAL SAN MARTÍN   (Argentina)

^b Sanatorio Itoiz   (Argentina)

^c Hospital Zonal General de Agudos Dr Carlos Bocalandro   (Argentina)

^d HOSPITAL MACIEL   (Uruguay)

^e FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

^f Unidad de Cuidados Intensivos   (Chile)

^g HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^h PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

ⁱ Fundacion Centro de Estudios Infectologicos   (Argentina)

^j Clinica y Maternidad Suizo Argentina   (Argentina)

^k UNIVERSIDAD DEL VALLE   (Colombia)

^l Hospital Héroes de Malvinas   (Argentina)

^m Universidad de Sao Pablo   (Brazil)

ⁿ Fundación Neumo nológica   (Colombia)

more..

Author keywords

Guidelines and respiratory infection; Pneumonia

Indexed keywords

EID: 77955566194     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (210)

1. National Center for Health Statistics.National hospital discharge survey: Annual summary 1990.Vital Health Stat 1998; 13: 1-225.
2. Niederman M S, Peter S P.Update in pulmonary medicine.Ann Intern Med 1998; 128: 208-15.
3. Niederman M S, McCombs J S, Unger A N, Kumar A, Popovian R.The cost of treating community-acquired pneumonia.Clin Ther 1998; 20: 820-37.
4. Calmaggi A, Clara L, González Arzac M, López Furst M J, Levy Hara G.Guías para el diagnóstico y tratamiento de la neumonía adquirida en la comunidad en adultos.Infect Microbiol Clin 2000; 12: S6-S30.
5. Bartlett J G, Dowell S F, Mandell L A, File T M Jr, Musher D M, Fine M J.Practice guidelines for the management of community-acquired pneumonia in adults.Clin Infect Dis 2000; 31: 347-82.
6. Mandell L A, Marrie T J, Grossman R F, Chow A W, Hyland R H.Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.Clin Infect Dis 2000; 31: 383-421.
7. Huchon G, and European Study on Community-acquired Pneumonia.Guidelines for management of adult community-acquired lower respiratory tract infections.Eur Respir J 1998; 11: 986-91.
8. Niederman M S, Mandell L A, Anzueto A, Bass J B, Broughton W A, Campbell GD, et al.Guidelines for management of adults with community-acquired pneumonia.Am J Resp Crit Care Med 2001; 163: 1730-54.
9. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.Thorax 2001; 56 (Suppl 4): iv1-iv64.
10. SEPAR, Spanish Thoracic Society.National recommendations for diagnosis and treatment of community acquired pneumonia.Barcelona, Spain.Ediciones Doyma 1992.
11. Woodhead M.Community-acquired Pneumonia Guidelines.An international comparison.A view from Europe.Chest 1998; 113: S183S-S187.
12. Luna C M, Efron E D, Schiavi E, Gene R J, Famiglietti A, Jolly E C, et al.Community-acquired pneumonia in adults.Clinical practice guideline for Argentina.Study Group on Community Acquired Pneumonia.Medicina (Buenos Aires) 1997; 57: 343-55.
13. Da Cunha C A, Sader H S, Nicodemo A C.Brazilian Society for Infectious Diseases Practice Guidelines Committee.Antimicrobial therapy for community-acquired pneumonia in adults.Braz J Infect Dis 2002; 6: 82-7.
14. Luna C M, Famiglietti A, Absi R, Videla A J, Noqueira F J, Fuenzalida A D, et al.Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina.Chest 2000; 118: 1344-54.
15. Jasovich A, Soutric J, Morera G, Mastruzzo M, Vesco E, Izaguirre M, et al.Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia.A clinical trial based on a pharmacodynamic model.J Chemother 2002; 14: 591-6.
16. Cabello H, Cortés C, Ruiz M, Jover E, Rivera F, Segovia E, et al.Community acquired pneumonia.Report of 8 cases of severe pneumonia by serogroup 1 Legionella pneumophila in Chile.Rev Med Chile 2002; 130: 309-13.
17. Bantar, C, Bavestrello, L, Curcio, D, Jasovich A, Absi R, Bagnulo H, et.al.Acute community-acquired pneumonia in adults: guidelines for initial antimicrobial therapy based on local evidence from a South American Working Group (ConsenSur).J Chemother 2002; 14 (Suppl 4): 1-22.
18. Kish M A.Guide to development of practice guidelines.Clin Infect Dis 2001; 32: 851-4.
19. Gross P A, Barret T L, Dellinger P, Krause P J, Martone W J, McGowan J E Jr, et al.Purpose of quality standards for infectious diseases.Clin Infect Dis 1994; 18: 421-7.
20. Guillemot D, Maison P, Carbon C, Balkau B, Vauzelle-Kervroëdan F, Sermet C, et al.Trends in antimicrobial use in the community-France, 1981-1992.J Infect Dis 1998; 177: 492-7.
21. Polk R.Optimal use of modern antibiotics: emerging trends.Clin Infect Dis 1999; 29: 264-74.
22. Okeke I, Lamikanra A, Edelman R.Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotic in developing countries.Emerg Infect Dis 1999; 5: 18-27.
23. Marrie T, Lau C, Wheeler S, Wong C J, Feagan B G.Predictors of symptom resolution in patients with community-acquired pneumonia.Clin Infect Dis 2000; 31: 1362-7.
24. Metlay J P, Atlas S J, Borowsky L H, Singer D E.Time course of symptom resolution in patients with community-acquired pneumonia.Respir Med 1998; 92: 1137-42.
25. Gonzales R, Steiner J F, Sande M A.Antibiotic prescribing for adults with colds, upper respiratory tract infections and bronchitis by ambulatory care physicians.JAMA 1997; 278: 901-4.
26. Gonzales R, Steiner J F, Lum A, Barrett P H Jr.Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults.JAMA 1999; 281: 1512-9.
27. Wipf J E, Lipsky B A, Hirschmann J V, Boyko E J, Takasugi J, Peugeot R L, et al.Diagnosing pneumonia by physical examination: relevant or relic? Arch Intern Med 1999; 159: 1082.
28. Metlay J P, Kapoor W N, Fine MJ.Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination.JAMA 1997; 278: 1440-5.
29. Niederman M S, Bass J B Jr, Campbell G D, Fein A M, Grossman R F, Mandell L A, et al.American Thoracic Society guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy.American Thoracic Society.Medical Section of the American Lung Association.Am Rev Respir Dis 1993; 148: 1418-26.
30. Bartlett J G, Breiman R F, Mandell L A, File T M Jr.Community-acquired pneumonia in adults: guidelines for management.Clin Infect Dis 1998; 26: 811-38.
31. Fine M J, Auble T E, Yealy D M, Hanusa B H, Wiessfeld L A, Singer D E, et al.A prediction rule to identify low-risk patients with community-acquired pneumonia.N Engl J Med 1997; 336: 243-50.
32. Marston B J, Lipman H B, Breiman R F.Surveillance for Legionnaires' disease: risk factors for morbidity and mortality.Arch Intern Med 1994; 154: 2417-22.
33. Sabrià M, Pedro-Botet M L, Gómez J, Roig J, Vilaseca B, Sopena N, et al.Fluoroquinolones vs macrolides in the treatment of Legionnaires disease.Chest 2005; 128: 1401-5.
34. Blázquez Garrido R M, Espinosa Parra F J, Alemany Francés L, Ramos Guevara R M, Sánchez-Nieto J M, Segovia Hernández M, et al.Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides.Clin Infect Dis 2005; 40: 800-6.
35. Baddour L M, Yu V L, Klugman K P, Feldman C, Ortqvist A, Rello J, et al.Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.Am J Respir Crit Care Med 2004; 170: 440-4.
36. Pachon J, Prados M D, Capote F, Cuello J A, Garnacho J, Verano A.Severe community-acquired pneumonia: etiology, prognosis and treatment.Am Rev Respir Dis 1990; 142: 369-73.
37. Levy M, Dromer F, Brion N, Leturdu F, Carbon C.Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations.Chest 1988; 93: 43-8.
38. Leroy O, Santre C, Beuscart C.A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU.Intensive Care Med 1995; 21: 24-31.
39. Gleason P P, Meehan T P, Fine J M, Galusha D H, Fine M J.Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.Arch Intern Med 1999; 159: 2562-72.
40. Woodhead M A, Arrowsmith J, Chamberlain-Webber R, Wooding S, Williams I.The value of routine microbial investigation in community-acquired pneumonia.Respir Med 1991; 85: 313-7.
41. Benito J R, Montejo J M, Cancelo L, Zalacaín R, López L, /xnamexFerna ́ndez Gil de Pareja/x/namex S, et al.Community-acquired pneumonia due to Legionella pneumophila serogroup 1.Study of 97 cases] Enferm Infecc Microbiol Clin 2003; 21: 394-400.
42. Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Jinnai M.A 3-year prospective study of a urinary antigen-detection test for Streptococcus pneumoniae in community-acquired pneumonia: utility and clinical impact on the reported etiology.J Infect Chemother 2004; 10: 359-63.
43. Lasocki S, Scanvic A, Le Turdu F, Restoux A, Mentec H, Bleichner G, et al.Evaluation of the Binax NOW Streptococcus pneumoniae urinary antigen assay in intensive care patients hospitalized for pneumonia.Intensive Care Med 2006; 32: 1766-72.
44. Luna C M, Brea Folco J, Aruj P, Reboca K, Balselre C, Dosi R, et al.Pneumonia due to Legionella pneumophila.Experience gathered in a University Hospital in Buenos Aires.Medicina (B Aires) 2004; 64: 97-102.
45. Chedid M B, Ilha Dde O, Chedid M F, Dalcin P R, Buzzetti M, Jaconi Saraina P, et al.Community-acquired pneumonia by Legionella pneumophila serogroups 1-6 in Brazil.Respir Med 2005; 99: 966-75.
46. Lopardo G, Sturba E, Martínez ML, Roel JE, Gamba A, Biondi H, et al.Detección de infección aguda por Legionella pneumophila en pacientes con neumonía adquirida en la comunidad en la ciudad de Buenos Aires.Medicina (Buenos Aires) 2002; 62: 145-8
47. Bates J H, Campbell G D, Barron A L, McCracken G A, Morgan P N, Moses E B, et al.Microbial etiology of acute pneumonia in hospitalized patients.Chest 1992; 101: 1005-12.
48. Fang G D, Fine M, Orloff J, Arisumi D, Yu V L, Kapoor W, et al.New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases.Medicine 1990; 69: 307-16.
49. Marrie T J, Durant H, Yates L.Community-acquired pneumonia requiring hospitalization: 5-year prospective study.Rev Infect Dis 1989; 11: 586-99.
50. Fine M J, Smith M A, Carson C A, Mutha SS, Sankey S S, Weissfeld L A, et al.Prognosis and outcomes of patients with community-acquired pneumonia.JAMA 1996; 275: 134-41.
51. Levy M, Dromer F, Brion N, Leturdu F, Carbon C.Community-acquired pneumonia.Importance of initial noninvasive bacteriologic and radiographic investigations.Chest 1988; 93: 43-8.
52. Bianchini H, Bantar C, Schuster M, Smayevsky J, Micucci M.Limitation of the sputum in the diagnosis of lower respiratory tract infections.Acta Bioq Latin 1991; 15: 423-8.
53. Matta M, Buu Hoï A, Varon E, Gutmann L, Mainardi J L, et al.Impact of a positive Binax NOW /Streptococcus pneumo niae/ urinary antigen test on antibiotics policy.18th European Congress of Clinical Microbio logy and Infectious Diseases, Barcelona 2008; Abstr P1290.
54. Díaz A, Barría P, Niederman M, Restrepo M I, Dreyse J, Fuentes G, et al.Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens.Chest 2007; 131: 779-87.
55. Moreno B R, Riquelme O R.Etiology of community-acquired pneumonia in immunocompetent adults.Rev Chil Infect 2005; 22 (Suppl 1): s18-25.
56. Luna C M, Calmaggi A, Caberloto O, Gentile J, Valentini R, Ciruzzi J, et al.Pneumonia acquired in the community.Practical guide elaborated by a committee intersocieties.Medicina (B Aires) 2003; 63: 319-43.
57. Nicodemo A C.An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.Braz J Infect Dis 2003; 7: 62-8.
58. Hortal M, Ruvinsky R, Rossi A, Agudelo C I, Castaneda E, Brandileone C, et al.Impact of Streptococcus pneumoniae on pneumonia in Latin American children.SIREVA-Vigía Group.Rev Panam Salud Publica 2000; 8: 185-95.
59. Calver A, Walsh N, Quinn P, Baran C, Lonergan V, Singh K P, et al.Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection.Clin Infect Dis 1997; 24: 570-4.
60. Milano E, Mazzini A, Suárez E, Pedreira W, Failache R, Torres J.Community's acute pneumonia.Multi-centered etiological survey-July 96-September 97.Arch Med Int 1998; 3: 107-11.
61. Fine M J, Smith M A, Carson C A, Mutha S S, Sankey S S, Weissfeld L A, et al.Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis.JAMA 1996; 275: 134-41.
62. Soca A, Bazet C, Battistesa S, Bono C, Elicabe M, Bentancourt S.Severe community-acquired pneumonia.Pac Crit 1999; 12: 96-107.
63. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J; CAP5 Moxifloxacin Study Group.Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.Chest 2001; 119: 185-95.
64. Lobos T, Saldías F, Cartagena C, Jover E, Álvarez M, Moreno R.Chlamydia pneumoniae in patients with acquired pneumonia in the Santiago of Chile community.Rev Med Chile 1998; 126: 1483-9.
65. Finegold S M.Aspiration pneumonia.Rev Infect Dis 1991; 13 (Suppl 9): S737-42.
66. Kaplan S L, Mason E O Jr.Management of infections due to antibiotic-resistant Streptococcus pneumoniae.Clin Microbiol Rev 1998; 11: 628-44.
67. Lister P D.Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections.Eur J Clin Microbiol Infect Dis 1995; 14 (Suppl 1): S18-25.
68. Jacobs M R, Bajaksouzian S, Zilles A, Lin G, Pankuch G, Appelbaum P C.Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S.surveillance study.Antimicrob Agents Chemother 1999; 43: 1901-08.
69. Hoban D J, Doern G V, Fluit A C, Roussel-Delvallez, Jones R N.Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1977-1999.Clin Infect Dis 2001; 32 (Suppl 2): S81-93.
70. Sader H S, Gales A C, Granacher T D, Pfaller M A, Jones R N; The SENTRY Study Group (Latin America).Prevalence of antimicrobial resistance among respiratory tract isolates in Latin America: results from SENTRY antimicrobial surveillance program (1997-98).Braz J Infect Dis 2000; 4: 245-54.
71. Jacobs M R, Appelbaum P C.Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries.Laser Study Group.Int J Antimicrob Agents 2000; 16: 17-24.
72. Guzmán-Blanco M, Casellas J M, Sader H S.Bacterial resistance to antimicrobial agents in Latin America.The giant is awakening.Infect Dis Clin North Am 2000; 14: 67-81.
73. Famiglietti A, Bantar C, Casellas J M, Golas M, Gutkind G, Kovensky J, et al.Sistema Informático de Resistencia (SIR).Análisis de prevalencia del año 2000.Boletín No 153.Asoc Arg Microbiol 2002; 153: 5-8.
74. Appelbaum P C.Resistance among Streptococcuspneumoniae:Implications fordrug selection.Clin Infect Dis 2002; 34: 1613-20.
75. Critchley I A, Thornsberry C, Piazza G, Jones M, Hickey M L, Barth A L, et al.Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil 1997-98.Clin Microbiol Infect 2000; 6: 178-84.
76. Thornsberry C, Brown N P, Draghi D C, Evangelista A T, Yee Y C, Sahm D F.Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005.Postgrad Med 2008;120 (3 Suppl 1): 32-8.
77. Sahm D F, Brown N P, Draghi D C, Evangelista A T, Yee Y C, Thornsberry C.Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.Postgrad Med 2008; 120 (3 Suppl 1): 8-15.
78. Critchley I A, Brown S D, Traczewski M M, Tillotson G S, Janjic N.National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S.Faropenem surveillance study.Antimicrob Agents Chemother 2007; 51: 4382-9.
79. Gravet A, Camdessoucens G, Murbach V, Barrand P, Boucher A, Boulenc A, et al.Evolution of antibiotic resistance of Streptococcus pneumoniae: results of Alsace observatory in 2005.Pathol Biol (Paris) 2007; 55: 424-8.
80. Morrissey I, Colclough A, Northwood J.Targeted surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents.Int J Antimicrob Agents 2007; 30: 345-51.
81. Borer A, Meirson H, Peled N, Porat N, Dagan R, Fraser D, et al.Antibiotic-resistant pneumococci carried by young children do not appear to disseminate to adult members of a closed community.Clin Infect Dis 2001; 33: 436-44.
82. Heffelfinger J D, Dowell S F, Jorgensen J H, Klugman K P, Mabry L R, Musher D M, et al.Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group.Arch Intern Med 2000; 160: 1399-408.
83. Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement.January 2009.M100-S19; Vol 29 No.3: 72-5.
84. Bagnulo H, Laserra J, Piñeyro L, Kubin R, McGivern J, Bobbaers H, et al.An open non-comparative study of the efficacy and tolerance of azithromycin in the treatment of patients with acute lower respiratory tract infections.Arch Med Int 1996; 1: 47-51.
85. Finch R, Schürmann D, Collins O, Kubin R, McGivern J, Bobbaers H, et al.Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v.and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.Antimicrob Agents Chemother 2002; 46: 1746-54.
86. Garau J, Twynholm M, García-Méndez E, Siquier B, Rivero A; 557 Clinical Study Group.Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults J Antimicrob Chemother 2003; 52: 826-36.
87. File T M Jr, Lode H, Kurz H, Kozak R, Xie H, Berkowitz E, et al.Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults Antimicrob Agents Chemother 2004, 48: 3323-31.
88. Siquier1 B, Sánchez-Álvarez J, García-Méndez E, Sabriá M, Santos J, Pallarés R, et al.Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/ clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.J Antimicrob Chemother 2006;57: 536-45.
89. Jasovich A, Curcio D, Prieto S, Bustos J, Mastruzzo M, Tosello C, et al.Frecuencia de Streptococcus pneumoniae penicilina-resistente (SpR) en adultos con neumonía adquirida en la comunidad (NAC): racionalidad de los esquemas terapéuticos empíricos basados en los sistemas de vigilancia de resistencia bacteriana.X Congreso Panamericano de Infectología.Guadalajara, México 2001, Abstr 59.
90. File T M, Jr.Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae.Clin Infect Dis 2002; 34: S17-S26.
91. Aspa J, Rajas O, Rodríguez de Castro F.Drug-resistant pneumococcal pneumonia: clinical relevance and related factors.Clin Infect Dis 2004; 38: 787-98.
92. File T M Jr, Tan J S, Boex J R.The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspective.Clin Infect Dis 2006; 42: 798-800.
93. Karstaedt A S, Khoosal M, Crewe-Brown H H.Pneumococcal bacteremia in adults in Soweto, South Africa, during the course of a decade.Clin Infect Dis 2001; 33: 610-14.
94. Mandell L, Wunderink R, Anzueto A, Bartlett J G, Campbell G D, Dean N C, et al.Infectious Diseases Society of America/ American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults.Clin Infect Dis 2007; 44: S27-72.
95. Artiles F, Horcajada-Herrera I, Noguera-Catalán J, Alamo-Antúnez I, Bordes-Benítez A, Lafarga-Capuz B: Macrolide-resistant Streptococcus pneumoniae on the islands of Gran Canaria and Lanzarote (Spain): molecular mechanisms and serogroup relationships.Enferm Infecc Microbiol Clin 2007; 25: 570-5.
96. Wierzbowski A K, Nichol K, Laing N, Hisanaga T, Nikulin A, Karlowsky J A, et al.Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).J Antimicrob Chemother 2007; 60: 733-40.
97. Hoban D J, Zhanel G G.Clinical implications of macrolide resistance in community-acquired respiratory tract infections.Expert Rev Anti Infect Ther 2006; 4: 973-80.
98. Reyes J, Hidalgo M, Díaz L, Rincón S, Moreno J, Vanegas N, et al.Characterization of macrolide resistance in Gram-positive cocci from Colombian hospitals: a countrywide surveillance.Int J Infect Dis 2007; 11: 329-36.
99. Bonofiglio L, Ojeda M I, de Mier C, Vay C, Famiglietti A, Gutkind G, et al.Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital.Int J Antimicrob Agents 2005; 25: 260-3
100. Smayevsky J, López H, Di Chiara M, Scarano S, Lanza A, Vilches V, et al.Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.Diag Microbiol Infect Dis 2000; 37: 261-4.
101. Pihlajamäki M, Kotilainen P, Kaurila T.Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents.Clin Infect Dis 2001; 33: 483-8
102. Stephens D S, Zughaier S M, Whitney C G, Baughman W S, Barker L, Gay K, et al.Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.Lancet 2005; 365: 855-63.
103. Lonks J R, Garau J, Gómez L, Xercavins M, Ochoa de Echagüen A, Gareen IF, et al.Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae.Clin Infect Dis 2002; 35: 556-64.
104. Klugman K P.Editorial commentary: antibiotic selection of multiply resistant pneumococci.Clin Infect Dis 2001; 33: 489-91.
105. Daneman N, Low D E, McGeer A, Green K A, Fisman D N.At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia.Clin Infect Dis 2008; 46: 1131-8.
106. Chen D K, Mcgeer A, De Azavedo J C, Low D E.Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.N Engl J Med 1999; 341: 233-9.
107. Ho P L, Que T L, Tsang D N, Ng T K, Chow K H, Seto W H.Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.Antimicrob Agents Chemother 1999; 43: 1310-3.
108. Wise R, Brenwald N, Gill M, Fraise A.Streptococcus pneumoniae resistance to fluoroquinolones.Lancet 1996; 348: 1660.
109. Goldsmith C E, Moore J E, Murphy P C, Ambler J E.Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.J Antimicrob Chemother 1998; 41: 420-1.
110. Ho P L, Tse W S, Tsang K W, Kwok T K, Ng T K, Cheng V C, et al.Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.Clin Infect Dis 2001; 32: 701-7.
111. Weiss K, Restieri C, Gauthier R.A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.Clin Infect Dis 2001; 33: 517-22.
112. Rittenhouse S F, Miller L A, Kaplan R L, Mosely GH, Poupard J A.A survey of beta-lactamase-producing Haemophilus influenzae.An evaluation of 5750 isolates.Diagn Microbiol Infect Dis 1995; 21: 223-5.
113. Jones R N, Jacobs M R, Washington J A, Pfaller M A.A 1994-95 survey of Haemophilus influenzae susceptibility to ten orally administered agents.A 187 clinical laboratory center sample in the United States.Diagn Microbiol Infect Dis 1997; 27: 75-83.
114. th International Congress on Infectious Disease.Buenos Aires 2000; Abstr.3.002.
115. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piñer R, et al.Severe Community-acquired pneumonia: Validation of the Infectious Diseases Society of America/ American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission.Clin Infect Dis 2009; 48: 377-85.
116. Angus D C, Marrie T J, Obrosky D S, Clermont G, Dremsizov T T, Coley C, et al.Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria.Am J Respir Crit Care Med 2002; 166: 717-23.
117. Valencia M, Badia J R, Cavalcanti M, Ferrer M, Agusti C, Angrill J, et al.Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores.Chest 2007; 132: 515-22.
118. Kauppinen M T, Herva E, Kujala P, Leinonen M, Saikku P, Syriälä H.The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland.J Infect Dis 1995; 172: 1330-5.
119. Neill A M, Martín J R, Weir R, Anderson R, Cherevshsky A, Epton M J, et al.Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission.Thorax 1996; 51: 1010-6.
120. Lim W S, van der Eerden M M, Laing R, Boersma W G, Karalus N, Town G I, et al.Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.Thorax 2003; 58: 377-82.
121. Fine M J, Auble T E, Yealy D M, Hanusa B H, Wiessfeld L A, Singer D E, et al.A prediction rule to identify low-risk patients with community-acquired pneumonia.N Engl J Med 1997; 336: 243-50.
122. British Thoracic Society, Myint P K, Kamath A V, Vowler S L, Maisey D N, Harrison B D: Severity assessment criteria recommended by the British Thoracic Society (BTS) for community-acquired pneumonia (CAP) and older patients.Should SOAR (systolic blood pressure, oxygenation, age and respiratory rate) criteria be used in older people? A compilation study of two prospective cohorts.Age Ageing 2006; 35: 286-91.
123. Charles P G, Wolfe R, Whitby M, Fuller A J, Stirling R, Wright A A, et al.SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia.Clin Infect Dis 2008; 47: 375-84.
124. Challen K, Bright J, Bentley A, Walter D.Physiological-social score (PMEWS) vs CURB-65 to triage pandemic influenza: a comparative validation study using community-acquired pneumonia as a proxy.BMC Health Serv Res 2007; 7: 33.
125. Fine M J, Hough L J, Medsger A R, Li Y H, Ricci E M, Singer D E, et al.The hospital admission decision for patients with community-acquired pneumonia: results from the pneumonia Patient Outcomes Research Team cohort study.Arch Intern Med 1997; 157: 36-44.
126. Fine M J, Medsger A R, Stone R A, Marrie T J, Coley C M, Singer D E, et al.The hospital discharge decision for patients with community-acquired pneumonia.Results from the pneumonia Patient Outcomes Research Team cohort study.Arch Intern Med 1997; 157: 47-56.
127. Marrie T J, Lau C Y, Wheeler S L, Wong C J, Vandervoot M K, Feagan B G.A controlled trial of a critical pathway for treatment of community-acquired pneumonia.CAPITAL Study Investigators.Community-acquired pneumonia intervention trial assessing levofloxacin.JAMA 2000; 283: 749-55.
128. Renaud B, Coma E, Labarere J, Hayon J, Roy P M, Boureaux H, et al.Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study.Clin Infect Dis 2007; 44: 41-9.
129. Labarere J, Stone R, Obrosky D, Yealy D M, Meehan T P, Fine J M, et al.Comparison of outcomes for low-risk outpatients and inpatients with pneumonia.Chest 2007 131: 480-8
130. Ananda-Rajah M R, Charles P G, Melvani S, Burrell L L, Johnson P D, Grayson M L.Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia.Scand J Infect Dis 2008; 40: 293-300.
131. Rello J, Rodríguez A.Severity of illness assessment for managing community-acquired pneumonia.Intensive Care Med 2007; 33: 2043-4.
132. Rosón B, Carratalá J, Dorca J, Casanova A, Manresa F, Gudiol F.Etiology, reasons for hospitalization, risk classess, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria.Clin Infect Dis 2001; 33: 158-65.
133. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, et al.Guidelines for the management of adult lower respiratory tract infections.Eur Respir J 2005; 26: 1138-80.
134. Mundy L M, Oldach D, Auwaerter P G, Gaydos C A, Moore R D, Bartlett J G, et al.Implications for macrolide treatment in community-acquired pneumonia.Hopkins CAP Team.Chest 1998; 113: 1201-6.
135. Aubier M, Verster R, Regamey C, Geslin P, Vercken J B.Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults.Clin Infect Dis 1998; 26: 1312-20.
136. O'Doherty B, Dutchman D A, Pettit R, Maroli A.Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.J Antimicrob Chemother 1997; 40 (Suppl A): 73-81.
137. Tremolieres F, de Kock F, Pluck N, Daniel R.Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.Eur J Clin Microbiol Infect Dis 1998; 17: 447-53.
138. Johnson D M, Stilwell M G, Fritsche T R, Jones R N; Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003).Diagn Microbiol Infect Dis 2006; 56: 69-74.
139. Castanheira M, Gales A C, Mendes R E, Jones R N, Sader H S.Antimicrobial susceptibility of Streptococcus pneumoniae in Latin America: results from five years of the SENTRY Antimicrobial Surveillance Program.Clin Microbiol Infect 2004; 10 (7): 645-51.
140. Ramírez J, Unowsky J, Talbot G H, Zhang H, Townsend L.Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.Clin Ther 1999; 21: 103-17.
141. th International Conference on Antimicrobial Agents and Chemotherapy.Washington, DC: American Society for Microbiology, 1997, page 378.
142. Moola S, Hagberg L, Churchyard G A, Dylewski J S, Sedani S, Staley H, et al.Comparison of grepafloxacin with clarithromycin in the treatment of community-acquired pneumonia (CAP).Chest 1999; 116: 974-983.
143. th International Conference on Antimicrobial Agents and Chemotherapy.Washington, DC: American Society for Microbiology, 1997.Abstr.LM 73 page 378.
144. Fogarty C, Grossman C, Williams J, Haverstock D, Church D.Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia.Infect Med 1999; 16: 748-63.
145. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C; Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin.Chest 1996; 110: 1499-506.
146. Bantar C, Nicola F, Fernández Canigia L, Arenoso H J, Soutric C, Montoto M, et al.A pharmacodynamic model to support a twelve-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.J Chemother 2000; 12: 223-27.
147. Bantar C, Nicola F, Fernández Canigia L, Arenoso H J, Soutric J, Montoto M, et al.Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through a pharmacodynamic analysis in the setting of amino penicillin-resistant organisms.J Chemother 2001; 13: 402-6.
148. Drusano G L, Craig W A.Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.J Chemother 1997; 3: 38-44.
149. th International Conference on Antimicrobial Agents and Chemotherapy.Washington, DC: American Society for Microbiology, 1997.
150. th International Conference on Antimicrobial Agents and Chemotherapy.Washington, DC: American Society for Microbiology, 1998.
151. Kelley M A, Weber D J, Gilligan P, Cohen M S.Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin.Clin Infect Dis 2000; 31: 1008-11.
152. Lisby G, Brasholt M S, Teglbjerg M S.Bacteremia and meningitis caused by a macrolide-sensitive strain of Streptococcus pneumoniae during treatment with azithromycin.Clin Infect Dis 2001; 33: 415-6.
153. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al.Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin.Eur Respir J 1995; 8: 1999-2007.
154. Phillips S L, Branaman-Phillips J.The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home-acquired pneumonia.J Am Geriatr Soc 1993; 41: 1071-4.
155. Ortiz-Ruiz G, Caballero-López J, Friedland I R, Woods G L, Carides A; Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group.A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults.Clin Infect Dis 2002; 34: 1076-83.
156. Poirier R, Chardon H, Beraud A, Debieuvre D, Petitprez P, Montestruc F, et al.Efficacy and tolerability of pristinamycin vs amoxicillin-clavulanic acid combination in the treatment of acute community-acquired pneumonia in hospitalized adults.Rev Pneumol Clin 1997; 53: 325-31.
157. Rosón B, Carratalá J, Tubau F, Dorca J, Linares J, Pallares R, et al.Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.Microb Drug Resist 2001; 7: 85-96.
158. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, et al.Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.Antimicrob Agents Chemother 1998; 42: 53-8.
159. Bantar C, Famiglietti A, Goldberg M, The Antimicrobial Committee and The National Surveillance Program (SIR) Participants Group.Three-year surveillance study of nosocomial bacterial resistance in Argentina.Int J Infect Dis 2000; 4: 85-90.
160. Sader H S, Gales A C, Pfaller M A, Mendes R E, Zoccoli C, Barth A, et al.Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY Antimicrobial Surveillance Program.Braz J Infect Dis 2001; 5: 200-14.
161. Bantar C, Famiglietti A, Radice M, Quinteros M.A 7-year national survey on bacterial resistance in bronchoalveolar lavage from patients hospitalized in Argentina.Diagn Microbiol Infect Dis 2008; 60: 65-9.
162. Sader H S, Jones R N, Gales A C, Silva J B, Pignatari A C.SENTRY antimicrobial surveillance program report: Latin American and Brazilian results for 1997 through 2001.Braz J Infect Dis 2004; 8: 25-79.
163. Bantar C, Sartori B, Vesco E, Heft C, Saúl M, Salamone F, et al.A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance.Clin Infect Dis 2003; 37: 180-6.
164. Williams D, Perri M, Zervos M J.Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia.Eur J Clin Microbiol Infect Dis 1994; 13: 293-8.
165. Stein G E, Mantz S L.Antibiotic utilization and cost analysis in hospitalized patients with community-acquired pneumonia.Hosp Pharm 1995; 30: 132-4.
166. Fogarty C, Dowell M E, Ellison W T, Vrooman P S, Jr, White B J, Mayer H.Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/ clarithromycin.J Resp Dis 1999; 20 (Suppl): S60-S69.
167. Norrby S R, Petermann W, Willcox P A, Vetter N, Salewski E.A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.Scand J Infect Dis 1998; 30: 397-404.
168. Nathwani D.Place of parenteral cephalosporins in the ambulatory setting: clinical evidence.Drugs 2000; 59 Suppl 3: 37-46.
169. th International Congress on Infectious Diseases.Buenos Aires, Argentina 2000, Abstr 70.002.
170. Plouffe J F.Importance of atypical pathogens of community-acquired pneumonia.Clin Infect Dis 2000; 31 (Suppl 2): S35-9.
171. Stahl J E, Barza M, DesJardin J, Martin R, Eckman M H.Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.Arch Intern Med 1999 Nov 22; 159 (21): 2576-80.
172. Tan J S, File T M Jr, Di Persio J R, DiPersio L P, Hamor R, Saravolatz L D, et al.Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila.Clin Infect Dis 2001; 32 (11): 1562-6.
173. Hohl P, Buser U, Frei R.Fatal Legionella pneumophila pneumonia: treatment failure despite early sequential oral-parenteral amoxicillin-clavulanic acid therapy.Infection 1992; 20: 99-100.
174. Ma X X, Galiana A, Pedreira W, Mowszowicz M, Christophersen I, Machiavello S, et al.Community-acquired methicillin-resistant Staphylococcus aureus, Uruguay.Emerg Infect Dis 2005; 11 (6): 973-6.
175. Paganini H, Della Latta M P, Muller Opet B, Ezcurra G, Uranga M, Aguirre C, et al.Community-acquired methicillin-resistant Staphylococcus aureus infections in children: multicenter trial.Arch Argent Pediatr 2008 Oct; 106 (5): 397-403.
176. Curcio D, Fernández F, Cané A, Barcelona L, Stamboulian D.Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry.Braz J Infect Dis 2008;12 (3): 198-201.
177. Munoz-Price L S, Lolans K, Quinn J P.Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline.Scand J Infect Dis 2006; 38 (11-12): 1081-4.
178. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al.Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.J Antimicrob Chemother 2008; 62 Suppl 1: i17-i28.
179. de Klerk G J, van Steijn J H, Lobatto S, Jaspers C A, van Veldhuizen W C, Hensing C A, et al.A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections.Int J Antimicrob Agents 1999; 12: 121-7.
180. Reingold A L.Role of Legionellae in acute infections of lower respiratory tract.Rev Infect Dis 1988; 10: 1018-28.
181. Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, Mensa J, et al.Severe community-acquired pneumonia: risk factors and follow-up epidemiology.Am J Respir Crit Care Med 1999; 160: 923-9.
182. Zhanel G G, Ennis K, Vercaigne L, Walkty A, Gin A S, Embil J, et al.A critical review of the fluoroquinolones: focus on respiratory infections.Drugs 2002; 62: 13-59.
183. Arnold F W, Summersgill J T, Lajoie A S, Peyrani P, Marrie T J, Rossi P, et al.A worldwide perspective of atypical pathogens in community-acquired pneumonia.Am J Respir Crit Care Med 2007; 175:1086-93.
184. Rodríguez A, Mendia A, Sirvent J M, Barcenilla F, de la Torre-Prados M V, Solé-Violán J, et al.Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock.Crit Care Med 2007; 35 (6): 1493-8.
185. Mykietiuk A, Carratalà J, Fernández-Sabé N, Dorca J, Verdaguer R, Manresa F, et al.Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy.Clin Infect Dis 2005; 40: 794-9.
186. Johnson C C, Livornese L, Gold M J, Pitsakis P G, Taylor S, Levinson M E.Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.Antimicrob Agents Chemother 1995; 35: 765-73.
187. Patterson J E, Hardin T C, Kelly M T, Jorgensen J H.Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae.Infect Control Hosp Epidemiol 2000; 21: 455-8.
188. Zervos M, Nelson M, and the Cefepime Study Group.Cefepime versus ceftriaxone for empiric treatment of hospitalized patients with community-acquired pneumonia.Antimicrob Agents Chemother 1998; 42: 729-33.
189. Speich R, Imhof E, Vogt M, Grossenbacher M, Zimmerli W.Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.Eur J Clin Microbiol Infect Dis 1998; 17: 313-7.
190. Bantar C, Di Chiara M, Nicola F, Relloso S, Smayevsky J.Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains.Diag Microbiol Infect Dis 2000; 37: 41-4.
191. Visalli M A, Jacobs M R, Appelbaum P C.Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome and meropenem against 124 strains of Pseudomonas aeruginosa by checkerboard and time-killing methodology.Antimicrob Agents Chemother 1998; 42: 953-5.
192. Gerceker A A, Gurler B.Invitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aerugi-nosa.J Antimicrob Chemother 1995; 36: 707-11.
193. Castanheira M, Jones R N, Livermore D M.Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.Diag Microbiol Infect Dis 2009; doi:10.1016/j.diagmicrobio.2009.01.026.
194. Feagan B G.A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study.Community-acquired pneumonia intervention trial assessing levofloxacin.Pharmacotherapy 2001; 21 (7 pt 2): 89s-94s.
195. Milkovich G.Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.Pharmacotherapy 2001; 21 (7 Pt 2): 83S-88S.
196. Hirata-Dulas C A, Stein D J, Guay D R, Gruninger R P, Peterson P K.A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections.J Am Geriatr Soc 1991; 39: 979-85.
197. Siegel R E, Halpen N A, Almenoll P N, Lee A, Cashin R, Greene J G.A prospective randomized study of inpatient i.v.antibiotics for community-acquired pneumonia: the optimal duration of therapy.Chest 1996; 110: 965-71.
198. Chan R, Hemeryck L, ÓRegan M, Clancy L, Feely J.Oral versus intravenous antibiotics for community-acquired lower respiratory tract infection in a general hospital: open, randomized, controlled trial.Br J Med 1995; 310: 360-2.
199. Dresser L D, Niederman M S, Paladino J A.Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.Chest 2001; 119: 1439-48.
200. Dowell S F.The best treatment for pneumonia.Arch Inter Med 1999; 159: 2511-12.
201. Christensen D, Feldman C, Rossi P, Marrie T, Blasi F, Luna C, et al.HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study.Clin Infect Dis 2005; 41:554-6.
202. Davison R, Cavalcanti R, Brunton J L, Bast D J, de Azavedo J C, Kibsey P, et al.Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.N Engl J Med 2002; 346: 747-50.
203. Fuller J D, Low D E.A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.Clin Infect Dis 2005; 41: 118-21.
204. Marik P E.Aspiration pneumonitis and aspiration pneumonia.N Eng J Med 2001; 344: 665-71.
205. Mier L, Dreyfuss D, Darchy B, Lanore J J, Djedaïni K, Weber P, et al.Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures.Intensive Care Med 1993; 19: 279-84.
206. Marik P E, Careau P.The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study.Chest 1999; 115: 178-83.
207. Levinson M E, Mangura C T, Lorber B, Abrutyn E, Pesanti E L, Levy R S, et al.Clindamycin compared with penicillin for the treatment of lung abscess.Ann Intern Med 1983; 98: 466-71.
208. Gudiol F, Manressa C T, Pallares R, Dorca J, Rufi G, Boada J, et al.Clindamycin vs penicillin for anaerobic lung infections: high rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus.Arch Inter Med 1990; 150: 2525-9.
209. Germaud P, Potrier J, Jacqueme P, Guerin J C, Benard Y, Boutin C, et al.Monotherapy using amoxicillin/clavulanic acid as treatment of first choice in community-acquired lung abscess.Rev Pneumol Clin 1993; 49: 137-41.
210. Saldias F, Flores L J, Torres C, García P, Díaz A.Susceptibilidad a antimicrobianos de Streptococcus pneumoniae en población infantil y adulta de Santiago: Período 1997-2003.Rev Med Chile 2005; 133: 42-9.